Holen Sie sich die Stockscreener-App
3.80
0.92%
-0.02
Schlusskurs vom Vortag:
$3.82
Offen:
$3.75
24-Stunden-Volumen:
1.29M
Relative Volume:
0.32
Marktkapitalisierung:
$1.38B
Einnahmen:
$3.06M
Nettoeinkommen (Verlust:
$-141.62M
KGV:
-5.168
EPS:
-0.7353
Netto-Cashflow:
$-78.67M
1W Leistung:
+11.65%
1M Leistung:
+6.02%
6M Leistung:
-18.25%
1J Leistung:
+172.30%
1-Tages-Spanne:
$3.7001
$3.90
1-Wochen-Bereich:
$3.38
$4.25
52-Wochen-Spanne:
$1.15
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
Firmenname
Ataibeckley Inc
Sektor
Branche
Telefon
49 89 2153 9035
Adresse
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN
Compare ATAI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
3.80 | 1.39B | 3.06M | -141.62M | -78.67M | -0.7353 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.41 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.32 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
702.94 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.06 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.93 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-20 | Eingeleitet | Guggenheim | Buy |
| 2025-10-13 | Eingeleitet | Needham | Buy |
| 2025-07-29 | Eingeleitet | Oppenheimer | Outperform |
| 2024-11-18 | Bestätigt | H.C. Wainwright | Buy |
| 2024-04-03 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2021-11-30 | Eingeleitet | Maxim Group | Buy |
| 2021-11-11 | Eingeleitet | ROTH Capital | Buy |
| 2021-10-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-09-01 | Eingeleitet | Jefferies | Buy |
| 2021-07-13 | Eingeleitet | Berenberg | Buy |
| 2021-07-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-13 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2021-07-13 | Eingeleitet | Citigroup | Buy |
| 2021-07-13 | Eingeleitet | Cowen | Outperform |
| 2021-07-13 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Ataibeckley Inc Aktie (ATAI) Neueste Nachrichten
AtaiBeckley plans Phase 3 trials for depression treatment in Q2 By Investing.com - Investing.com Nigeria
Why AtaiBeckley (ATAI) Is Up 10.0% After FDA Backs BPL-003 Phase 3 Depression Trials - simplywall.st
Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT in TRD; Psilocybin for Smoking Cessation Study Published - Psychedelic Alpha
ATAI: Short-duration psychedelic therapies show strong efficacy and commercial promise - TradingView
ATAI: Short-duration psychedelic therapies show strong efficacy and commercial promise in mental health - TradingView
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting, AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - marketscreener.com
H.C. Wainwright Maintains Buy on ATAI Atai Beckley N.V Mar 2026 - Meyka
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
Small cap wrap: Immunic, AtaiBeckley, Standard Uranium, Trust Stamp… - Proactive Investors
AtaiBeckley Social Anxiety Treatment A Game-Changer: AnalystsAtaiBeckley (NASDAQ:ATAI) - Benzinga
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - Investing News Network
AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor Day - Yahoo Finance
H.C. Wainwright reiterates atai Life Sciences stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates atai Life Sciences stock rating at buy - Investing.com
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Atai Beckley N.V. (ATAI) and Artivion (AORT) - The Globe and Mail
Atai Beckley advancing BPL-003 nasal spray towards Phase 3 after FDA meeting - TipRanks
AtaiBeckley Inc. Advances BPL-003 toward Phase 3 Trials for Treatment-Resistant Depression Following Positive Phase 2b Results - Quiver Quantitative
AtaiBeckley nasal spray for hard-to-treat depression eyes 2026 trials - Stock Titan
Assessing Atai (ATAI) Valuation After FDA Backing For BPL-003 And Positive EMP-01 Trial Results - simplywall.st
AtaiBeckley Exploring Potential Sale, Partnership for Psychedelic Drug Candidate - marketscreener.com
Atai Life Sciences Stock Poised for Gains Amid New FDA Trials Approval - timothysykes.com
FDA Supports AtaiBeckley’s New Depression Treatment Trials - StocksToTrade
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal - Psychedelic Alpha
AtaiBeckley’s FDA Backing And Trial Data Reframe Mental Health Upside And Risk - Yahoo Finance
4 Analysts Have This To Say About AtaiBeckley - Benzinga
AtaiBeckley Files For Mixed Shelf Offering - TradingView
Atai Beckley Inc (ATAI) has filed documents with the U.S. Securities and Exchange Commission (SEC) to allow selling shareholders to resell up to 74.3 million ordinary shares. - Bitget
AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003 - Insider Monkey
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
AtaiBeckley Advances Key Depression And Anxiety Programs As Losses Mount - Sahm
Ataibeckley (ATAI) to initiate phase 3 depression study following positive FDA meeting - MSN
AtaiBeckley weighing options for psychedelic drug (ATAI:NASDAQ) - Seeking Alpha
Atai Beckley is said to explore options for main psychedelic drugBloomberg News - marketscreener.com
AtaiBeckley Is Said To Explore Options For Main Psychedelic Drug- Bloomberg News - TradingView
AtaiBeckley Is Said to Explore Options for Main Psychedelic Drug - Bloomberg.com
10 Best New Penny Stocks to Buy - Insider Monkey
AtaiBeckley releases pro forma financials following Beckley Psytech acquisition - Investing.com Nigeria
Jefferies reiterates atai Life Sciences stock rating on pipeline progress - Investing.com
Small cap wrap: American Resources, AtaiBeckley, Alvopetro Energy… - Proactive Investors
AtaiBeckley: BPL-003 targets rapid, durable TRD relief with scalable, short in-clinic dosing and strong clinical data - TradingView
AtaiBeckley: BPL-003 offers rapid, durable TRD relief with scalable, short in-clinic dosing and strong phase 2b data - TradingView
AtaiBeckley’s MDMA product could treat social anxiety; HHS Secretary Kennedy talks psychedelics on Rogan podcast; WV Senate and SD legislature pass Compass trigger bills - The Microdose | Substack
ATAI Beckley earnings missed by $1.63, revenue topped estimates - Investing.com India
AtaiBeckley Reports Wider FY25 Loss, Highlights Progress Across Mental Health Pipeline, Stock Down - Nasdaq
AtaiBeckley reports 2025 results as it eyes Q2 start for Phase 3 depression trial - Proactive financial news
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update - Investing News Network
Atai Beckley sees cash runway into 2029 - TipRanks
Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints - Sahm
AtaiBeckley To Host Virtual Investor Day on March 6, 2026 - Investing News Network
Is It Time To Reassess AtaiBeckley (ATAI) After Its Recent Share Price Swings? - simplywall.st
Price to sales ratio of AtaiBeckley Inc. – XETR:B72 - TradingView
Finanzdaten der Ataibeckley Inc-Aktie (ATAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):